

Novel Phytochemical Inhibitors of Leptin: A Molecular Docking Approach for Potential Cardiovascular and Antidiabetic Therapies

Abdul Rauf¹, Sumayya Qazi², Bashir Ahmad Malik³, Sehar Aslam⁴, Urooj Anwar⁴,
Usman Ali Ashfaq⁴, Rashid Bhatti^{5*}

ABSTRACT

OBJECTIVE: To identify phytochemicals as potential leptin inhibitors, particularly in the context of immune and cardiovascular health, using molecular docking analysis.

METHODOLOGY: This study was conducted from 2023 to 2024 with the joint efforts of the Department of Bioinformatics and Biotechnology, Government College University Faisalabad, and the Center of Excellence and Molecular Biology, University of Punjab Lahore. The 3D structure of Leptin was retrieved from the Protein Data Bank and refined for docking analyses using PyRx. A ligand library consisting of 5,006 phytochemicals was prepared from various databases. The interactions were visualized using Discovery Studio. Compounds with high docking scores were further analyzed for their ADMET properties, based on Lipinski's Rule of Five, to ensure their drug-like characteristics and predict their safety profiles.

RESULTS: The compounds Peonidin, Diosmin, 7-[3-(3-hydroxy oct-1-enyl)-4,6-dioxabicyclo[3.1.1]heptan-2-yl] hept-5-exonic acid, Carnitine, Dihydrodaidzin, 4-dimethylpodophyllotoxin, 4-demethyldeoxypodophyllotoxin, (+)-sophorol and Tylophorinidine demonstrated successful binding to the Leptin. Thus, it potentially interferes with the leptin-leptin receptor interaction. Diosmin and Dihydrodaidzin showed the most vital binding score of -7.9 Kcal/mol of all the top-ranking compounds.

CONCLUSION: These compounds may act as effective inhibitors of Leptin, which may help develop natural, affordable therapies for cardiovascular disorders and diabetes. However, further research is required to validate their efficacy and safety.

KEYWORDS: Phytochemical Inhibitors, Leptin, Molecular Docking, Cardiovascular, Antidiabetic Therapies.

INTRODUCTION

Obesity has leading epidemic proportions and is the primary cause of cardiovascular diseases, diabetes, and comorbidity conditions like pulmonary hypertension. Leptin signalling has also been implicated in mood regulation¹. Research shows a strong connection between obesity and the development of leptin resistance as a potential biomarker and therapeutic target. Leptin plays a vital role in central energy metabolism and interacts significantly with the immune system². Leptin receptors influence both innate and adaptive immune responses. Additionally, many factors are linked to

obesity, leptin resistance, and bladder cancer³.

The leptin protein, composed of 167 amino acids, is primarily expressed in tissues such as the mammary gland, skeletal muscle, ovary, stomach, placenta, and lymphoid tissues, with the highest expression predominantly in white adipose tissue. The concentration level of circulating Leptin is directly linked to body fat levels, reflecting its role in long-term energy storage. Caloric intake fluctuations significantly impact leptin levels, with marked decreases during periods of starvation⁴. In mouse models, leptin receptor isoforms have the same ligand-binding site and show an alternative splicing pattern. The Ob-Re isoform is secreted into the bloodstream, while other Ob-R receptors are proteins located on the plasma membrane. The minor short forms of Ob-R receptors—Ob-Ra, c, d, and f—are involved in the specific intracellular signalling effects of leptin⁵. Leptin binding to the Ob-Rb receptor activates several signalling pathways, including the JAK-STAT pathway, MAPK pathways, and insulin receptor substrate⁶. The level of Leptin is measured usually high in obese patients. It plays a significant role in hypothalamic-pituitary function, regulating appetite, thermogenesis, and food intake. However, many obese individuals are resistant to elevated levels of circulating Leptin, with diet and body weight being critical factors in this resistance⁷. Leptin and insulin work together to

¹Department of Community Medicine, Sargodha Medical College Sargodha- Pakistan

²Department of Biochemistry, Liaquat Institute of Medical and Health Sciences, Thatta-Pakistan

³Social Security Hospital, Jauharabad (Khushab), Pakistan

⁴Department of Bioinformatics & Biotechnology, Government College University, Faisalabad-Pakistan

⁵Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan

Correspondence: rashid.bhatti@cemb.edu.pk

doi: 10.22442/jlumhs.2024.01187

Received: 03-09-2024

Revised: 04-10-2024

Accepted: 15-10-2024

Published Online: 17-10-2024



regulate long-term energy balance, as Leptin directly affects the liver and has insulin signaling pathways⁸. Obesity treatments can modulate leptin action in the brain, particularly in areas associated with food intake. LERP therapy has been effective in treating congenital leptin deficiency⁹.

The Ob-Ra isoform transports Leptin through the blood-brain barrier, while the Ob-Rb isoform intervenes in signal transduction and is shown to have high expression in the hypothalamus. Leptin is essential for maintaining metabolism, neuroendocrine function, bone metabolism and immune function. Recent studies suggest that excess Leptin can lead to hepatic inflammation and fibrosis¹⁰. Ongoing research investigates the potential of Leptin in treating non-alcoholic fatty liver disease, focusing on lipid handling, hepatic inflammation, and fibrosis. In contrast to mammals, Leptin does not affect food intake in non-mammals and may not be expressed in adipose tissue. Recent evidence suggests that increased expression of negative regulators in the hypothalamus is a crucial mechanism underlying leptin resistance¹¹. Using in silico methods is highly important in drug design, as it enables the screening of compound libraries through bioinformatics tools. Leptin is also associated with the progression of liver cancer, type II diabetes, and cardiac diseases, mainly myocardial infarction, ischemic stroke and peripheral vascular disease¹². Leptin, a cytokine family member, is encoded by the OB gene and produces a 16-kDa hormone named after the Greek word "leptos," meaning "lean." Due to its pro-inflammatory and anorexigenic functions, Leptin also exhibits several associated benefits in addressing malnutrition and inflammation, which are common in chronic kidney disease (CKD) patients and are linked to a high risk of cardiovascular morbidity and mortality¹³.

Moreover, Leptin's pro-inflammatory effects may cause kidney damage. This study aimed to investigate the role of the leptin protein in obesity and its associated comorbid conditions, including cardiovascular disease and diabetes. Furthermore, it also examines the role of Leptin as a potential biomarker and therapeutic target for developing strategies to treat obesity and related comorbid diseases, such as cardiovascular disease and diabetes.

METHODOLOGY

Study Location and Duration

This study was conducted from 2023 to 2024, with the joint efforts of the Department of Bioinformatics and Biotechnology at Government College University, Faisalabad, and the Centre of Excellence in Molecular Biology at the University of the Punjab, Lahore.

Protein Structure Retrieval and Preparation

The 3D structure of Leptin was retrieved from the Protein Data bank (PDB) using PDB ID: 3v6o. This structure was selected based on its high resolution and close resemblance with the native structural

confirmation of Leptin. The structure was refined by removing solvent residues and non-standardized ligands, and an accurate protonation state was assigned accordingly. This was followed by energy minimization using ChimeraX. This optimized structure was loaded into PyRx as a receptor for subsequent docking analyses.

Ligand Library Preparation

A library of 5006 phytochemicals was compiled from PubChem, MPD3, and MAPS databases. These phytochemicals were selected because of their drug-like properties. This library was subsequently prepared for molecular docking.

Molecular Docking

The prepared directory of phytochemicals was docked with Leptin's residues using the PyRx docking algorithm. Aicar (PubChem ID: 4), a known leptin inhibitor, was used as a reference ligand to validate docking results. The PyRx program ensured the perfect conformation of the ligands to achieve the lowest energy structure. The top docked compounds were selected based on their RMSD and Binding energy values. The Discovery Studio generated 2D receptor-ligand interaction plots, providing detailed visualizations of the interactions with docked complexes.

In-Silico Analysis of ADMET Properties

Compounds with the highest docking scores were further evaluated based on Lipinski's Rule of Five (Ro5), excluding those that violated this Rule. The molinspiration server was used to calculate the physicochemical properties. The drug-like features of the phytochemicals were then evaluated using the SwissADME web tool. ADMET properties were assessed to predict the behaviour of the drug candidates, including potential toxicity, ability to cross the blood-brain barrier, intestinal absorption, subcellular distribution, and overall safety profile.

RESULTS

Molecular Docking Analysis

From 5006 docked molecules, ten top-most docking poses were selected. These compounds were chosen based on binding site occupancy, minimum binding free energy, and lower RMSD values, exhibiting binding packet energies ranging from -7.9 Kcal/mol to -4.0 Kcal/mol (**Table I, Figure I**). Diosmin and Dihydrodaidzin emerged as the highest-ranking compounds with the strongest binding affinity among the selected binding sites. Two of the top ten phytochemicals, Diosmin and Dihydrodaidzin showed a strong binding affinity toward residues, TYR466, LYS486, GLN491, GLN501, PRO 502, ASP 532 and SER 541 respectively.

ADMET Analysis

All the selected candidates exhibited no violations of Lipinski's Rule of Five, demonstrating favourable drug-like properties, including an appropriate molar weight (**Table II**). These findings were further validated using the SwissADME server, with detailed results in **Table III**.

Table I: Top ten phytochemicals with docking scores and RMSD values

PubChem ID	Phytochemical name	Score	Value of RMSD
5281613	Diosmin	-7.9	3.3062
441773	Peonidin	-6	2.702
213	7-[3-(3-Hydroxyoct-1-enyl)-4,6-dioxabicyclo[3.1.1]heptan-2-yl]hept-5-enoic acid	-5.7	1.1910
288	Carnitine	-4.2	1.2157
10341941	Dihydrodaidzin	-7.8	2.0428
2116	DL-alpha-Tocopherol	-5.8	2.8407
122667	4'-Demethylpodophyllotoxin	-6.6	1.1309
23724667	(+)-Sophorol	-6.8	1.7353
161749	Tylophorinidine	-6.6	1.5286
160705	4'-Demethyldeoxypodophyllotoxin	-6.4	3.3220

Table II: Lipinski rule parameters for screened phytochemicals

Compounds	M. weight (g/mol) (<500)	Number of HBA (<10)	Number of HBD (<5)	MLogP (<5)
Diosmin	608.54g/mol	15	8	-3.23
Peonidin	301.27g/mol	6	4	0.57
7-[3-(3-Hydroxyoct-1-enyl)-4,6-dioxabicyclo[3.1.1]heptan-2-yl]hept-5-enoic acid	352.47g/mol	5	2	2.38
Carnitine	161.20g/mol	3	1	-3.79
Dihydrodaidzin	418.39g/mol	9	5	-0.92
DL-alpha-Tocopherol	430.71	2	1	6.14
4'-Demethylpodophyllotoxin	400.38g/mol	8	2	1.21
(+)-Sophorol	300.26g/mol	6	2	0.82
Tylophorinidine	365.42g/mol	5	2	2.00
4'-Demethyldeoxypodophyllotoxin	384.38g/mol	7	1	2.00

Table III: ADMET analysis parameters of active compounds

Compounds	Diosmin	Peonidin	7-[3-(3-Hydroxyoct-1-enyl)-4,6-dioxabicyclo[3.1.1]heptan-2-yl]hept-5-enoic acid	Carnitine	Dihydrodaidzin	DL-alpha-Tocopherol
1. Absorption						
Blood-brain barrier (BBB)	No	No	Yes	No	No	No
GI Absorption	Low	High	High	High	Low	Low
P-glycoprotein substrate	Yes	Yes	No	No	Yes	Yes
2. Metabolism						
CYP450 1A2 Inhibitor	No	Yes	No	No	No	No
CYP450 2C9 Inhibitor	No	No	Yes	No	No	No
CYP450 2D6 Inhibitor	No	No	Yes	No	No	No
CYP450 2C19 Inhibitor	No	No	No	No	No	No
CYP450 3A4 Inhibitor	No	No	Yes	No	No	No

DISCUSSION

The advent of in silico pharmacology has revolutionized drug design, significantly reducing the costs and time associated with traditional methods^{14,15}. Advanced bioinformatics tools and cheminformatics have enabled the screening of extensive compound libraries for drug-like properties¹⁶. In this study, 5006 phytochemicals were docked to recognize the potent leptin receptor inhibitors. Ten phytochemicals were identified as potential inhibitors, including Peonidin, Diosmin, 7-[3-(3-hydroxy oct-1-enyl)-4,6-dioxabicyclo[3.1.1]heptan-2-yl]hept-5-enoic acid, Carnitine, Dihydrodaidzin, 4-dimethylpodophyllotoxin, 4-demethyldeoxypodophyllotoxin, (+)-Sophorol, DL-alpha-Tocopherol, and Tylophorinidine, depending on their docking scores and binding affinity. Key residues, such as TYR466, LYS486, GLN491, GLN501, PRO502, ASP532, and SER541, were identified as critical for binding affinity in the best-docked compounds, Diosmin and Dihydrodaidzin (**Table I**)¹⁷. Leptin deficiency is primarily associated with insulin resistance, obesity, impaired glucose tolerance, and an increased risk of cardiovascular disease¹⁸. Obese individuals often exhibit higher leptin concentrations, highlighting the importance of developing leptin inhibitors as potential antidiabetic and anti-cancer agents. Previous studies have suggested various leptin inhibitors, but many have limitations^{19,20}. In contrast, our docking study identified ten potent phytochemicals with no ADMET violations, the highest docking scores, and the lowest RMSD values, providing a solid foundation for developing novel leptin inhibitors²¹. These ten phytochemicals yielded the highest docking scores from a large library of 5006 phytochemicals. They were chosen through non-covalent bonding, strong hydrogen bonds, and other thermodynamic factors, including binding energy. The top chemicals have binding energies ranging from -7.9 Kcal/mol to -4.0 Kcal/mol. Diosmin and Dihydrodaidzin showed the strongest binding score and the highest affinity among

all the top-ranking compounds, positioning them as possible leptin antagonists (**Table I**)²². After docking analysis, the physicochemical properties and drug-likeness (DL) of the selected inhibitors were assessed using the Molinspiration and SwissADME servers. The ADMET study demonstrated that the chosen inhibitors exhibited favourable pharmacokinetic profiles and complied with Lipinski's Rule of Five, indicating potential as inhibitors against Leptin (**Table II & III**)^{23,24}. Finding possible leptin antagonists can be done efficiently and economically using a molecular docking methodology and a phytochemical library. Particularly in the early phases of drug discovery, this computational screening eliminates the need for costly and time-consuming wet-lab studies. Compounds Diosmin and Dihydrodaidzin had a high binding affinity, indicating they could be potent leptin inhibitors. These results demonstrate that reported phytochemicals can interact with Leptin and may alter its action.

Since all the chosen compounds followed Lipinski's Rule of Five, they could be effective therapeutic agents for managing diseases associated with Leptin²⁵. The findings of this study will have a significant impact on the field of metabolic illnesses and obesity treatment.

Compared to synthetic drugs, the phytochemicals found in this work may provide a platform for developing new leptin inhibitors with greater bioavailability and fewer side effects. Furthermore, the discovery of distinct binding interactions between Leptin and essential amino acid residues (TYR466, LYS486, GLN491, GLN501, PRO 502, ASP 532 and SER 541) may direct the development of more effective and focused leptin antagonists (**Table I**)²⁵. Additionally, the increased interest in plant-based therapies is consistent with the possible application of natural substances as leptin inhibitors. Because they are typically considered safer and the body can handle them more effectively, phytochemicals are appealing options for long-term therapeutic plans. The results of this investigation contribute to the growing body of data on the use of natural ingredients in therapeutic development, particularly in the context of metabolic disorders¹⁷.


The study includes several limitations that should be noted despite the encouraging results. However, a handy tool, molecular docking is intrinsically constrained by its dependence on theoretical models and assumptions. The binding affinities and interactions seen *in silico* in a biological system might not always correspond to the same effectiveness. Confirming the binding potential and therapeutic efficacy of the discovered drugs requires experimental validation, such as *in vitro* and *in vivo* testing^{18,19}. The leptin structure found in the PDB (3v6o) was the only one that could be used for optimization and docking. Molecular docking simulations employ static structures, but protein structures undergo dynamic changes *in vivo*, including conformational shifts. A



more profound knowledge of how these phytochemicals interact with Leptin in a dynamic biological environment may be possible through a more thorough investigation using molecular dynamics simulations.

Furthermore, although the ADMET study shows beneficial pharmacokinetic features, it is still predicated on computational projections^{20,26}. More experimental investigations are needed, such as studies of absorption, distribution, metabolism, and excretion, to validate the pharmacokinetic characteristics of these substances. This study did not investigate other possible sources of leptin inhibitors, such as synthetic small molecules or peptides, and instead concentrated only on phytochemicals. While phytochemicals have many benefits, investigating additional chemical classes may yield more effective inhibitors or enhance the potential of discovered candidates as drugs²⁷.

Future study directions should include validating identified leptin inhibitors through experiments²⁸⁻³⁰. *In vitro* tests should be performed to determine the binding affinity and inhibitory potential of the chosen compounds, and *in vivo* experiments should be conducted to assess the effectiveness of the compounds in animal models of sickness associated with Leptin. Research utilizing site-directed mutagenesis for the TYR466, LYS486, GLN491, GLN501, PRO502, ASP532, and SER541 residues may validate the significance of these residues in leptin-phytochemical interactions, offering a more in-depth understanding of the inhibitory mechanism³¹. To better understand how phytochemicals interact with Leptin over time, molecular dynamics simulations can be used in conjunction with docking investigations³²⁻³⁷.

Figure I: Docking complexes of Leptin with most potent phytochemicals. 3D structures reveal the spatial interaction between the Leptin protein and phytochemicals. While 2D structures showed an interaction of phytochemicals with amino acid residues in the active site of Leptin



**Figure 1:**

A: Docking of Diosmin with Leptin displays hydrogen bonds formed by the side chain atoms of Tyr466, Lys486, Glu491, and Glu501, amino acids indicated in green colour. The carbon-hydrogen interaction with PRO 502 is shown in light green. The 2D interaction emphasizes the active residues within the receptor's binding pocket.

B: Docking of Peonidin shows that hydrogen bonds are formed by the side chain atoms of GLN 440, ASP 532, and ARG 615, amino acids (indicated in green). The 2D interaction depicts the active residues within Leptin's binding pocket.

C: Docking of 7-[3-(3-Hydroxyoct-1-enyl)-4,6-dioxabicyclo[3.1.1]heptan-2-yl]hept-5-enoic acid illustrates the formation of hydrogen bonds by the side chain atoms of ASP 532, ASN 567 amino acids (indicated in green). The 2D interaction diagram shows the active residues within the binding pocket of Leptin.

D: Docking of the Carnitine compound with Leptin displays hydrogen bonds formed by the side chain atoms of TRP 449, LYS 486, and TYR 489 amino acids. Carbon-hydrogen interaction with LYS 486 amino acid is indicated in green. The 2D interaction diagram emphasizes the active residues within the binding pocket.

E: Docking of the Dihydrodaidzin compound with Leptin shows the formation of hydrogen bonds by the side chains of ASP 532 and SER 541 amino acids (indicated in green). The 2D interaction diagram displays the active residues within the binding pocket of Leptin.

F: DL-alpha-Tocopherol docked complex illustrates the hydrogen bond and carbon-hydrogen interaction with side chain atoms of ASN 567 amino acid (indicated in green). The 2D interaction highlights the active residues within Leptin's binding pocket.

G: 4'-Demethylpodophyllotoxin docked complex with Leptin displays the formation of hydrogen bonds by the side chain atoms of ILE 489, ASP 489, GLU 457 and LYS 486 (indicated in green). The 2D interaction

emphasizes the active residues within Leptin's pocket. H: (+)-Sophorol docked complex with Leptin depicts the formation of hydrogen bonds by side chain atoms of TRP 449 (indicated in green). The 2D interaction shows the active residues within Leptin's binding pocket.

I: Tylophorinidine docked complex with Leptin shows the formation of carbon-hydrogen bonds by the side chain atoms of GLY 440 amino acid (indicated in light green). The 2D interaction highlights the active residues within Leptin's binding pocket.

J: 4'-Demethyldeoxypodophyllotoxin docked complex shows the formation of hydrogen bonds by the side chain atoms of GLU 437 and SER 533 (indicated in green). The 2D interaction emphasizes the active residues within the binding pocket.

CONCLUSION

A comprehensive phytochemical database of 5006 compounds was screened, leading to the identification of the top 10 leptin inhibitors, including Peonidin, Diosmin, 7-[3-(3-hydroxy oct-1-enyl)-4,6-dioxabicyclo [3.1.1]heptan-2-yl]hept-5-enoic acid, Carnitine, Dihydrodaidzin, 4-dimethylpodophyllotoxin, 4-demethyldeoxypodophyllotoxin, (+)-Sophorol, DL-alpha-Tocopherol, and Tylophorinidine. These compounds demonstrated the highest binding affinity and met the criteria for drug-like properties. Diosmin and Dihydrodaidzin exhibited the strongest binding affinity, making them promising candidates for drug development. Furthermore, *in vitro* and *in vivo* studies are necessary to evaluate their potential side effects and benefits for human use.

Ethical permission: This paper required no ethical permission because it is based on *in silico* studies.

Conflict of Interest: No conflicts of interest, as stated by authors.

Financial Disclosure/Grant Approval: No funding agency was involved in this research.

Data Sharing Statement: The corresponding author can provide the data proving the findings of this study on request. Privacy or ethical restrictions bound us from sharing the data publicly.

AUTHOR CONTRIBUTION

Rauf A: Writing original draft, methodology and formal Analysis

Qazi S: Formal Analysis

Malik BA: Methodology

Aslam S: Writing original draft

Anwar U: Writing original draft

Ashfaq UA: Conceptualization, supervision and validation

Bhatti R: Conceptualization and validation

REFERENCES

1. Vilariño-García T, Polonio-González ML, Pérez-

- Pérez A, Ribalta J, Arrieta F, Aguilar M et al. Role of Leptin in Obesity, Cardiovascular Disease, and Type 2 Diabetes. *Int J Mol Sci*. 2024; 25(4): 2338.
2. Askarpour M, Alizadeh S, Hadi A, Symonds ME, Miraghajani M, Sheikhi A et al. Effect of Bariatric Surgery on the Circulating Level of Adiponectin, Chemerin, Plasminogen Activator Inhibitor-1, Leptin, Resistin, and Visfatin: A Systematic Review and Meta-Analysis. *Horm Metab Res*. 2020; 52(4): 207-15.
3. Bruder-Nascimento T, Kress TC, Kennard S, Belin de Chantemele EJ. HIV Protease Inhibitor Ritonavir Impairs Endothelial Function Via Reduction in Adipose Mass and Endothelial Leptin Receptor-Dependent Increases in NADPH Oxidase 1 (Nox1), C-C Chemokine Receptor Type 5 (CCR5), and Inflammation. *J Am Heart Assoc*. 2020; 9(19): e018074.
4. Travers RL, Trim WV, Motta AC, Betts JA, Thompson D. Calorie restriction-induced leptin reduction and T-lymphocyte activation in blood and adipose tissue in men with overweight and obesity. *Int J Obesity*. 2024: 1-10.
5. Chang ML, Hsu CM, Tseng JH, Tsou YK, Chen SC, Shiau SS et al. Plasminogen activator inhibitor-1 is independently associated with non-alcoholic fatty liver disease, whereas Leptin and adiponectin vary between genders. *J Gastroenterol Hepatol*. 2015; 30(2): 329-36.
6. Clausen T, Djurovic S, Reseland JE, Berg K, Drevon CA, Henriksen T. Altered plasma concentrations of Leptin, transforming growth factor-beta(1) and plasminogen activator inhibitor type 2 at 18 weeks of gestation in women destined to develop pre-eclampsia. Circulating markers of disturbed placentation? *Placenta*. 2002; 23(5): 380-5.
7. Chiriaco M, Nesti L, Flyvbjerg A, Golay A, Nazare J-A, Anderwald C-H et al. At any level of adiposity, relatively elevated leptin concentrations are associated with decreased insulin sensitivity. *J Clin Endocrinol Metabol*. 2024; 109(2): 461-70.
8. Douros JD, Baltzegar DA, Breves JP, Lerner DT, Seale AP, Gordon Grau E et al. Prolactin is a major inhibitor of hepatic Leptin A synthesis and secretion: studies utilizing a homologous Leptin A ELISA in the tilapia. *Gen Comp Endocrinol*. 2014; 207: 86-93.
9. Şimşir İY, Özgür S, Soyaltın UE, Çetinkalp Ş. Effect of Dopamine Agonist Treatment on Glycemic Control in Patients with Lipodystrophy. *Endocrinol Res Pract*. 2024; 28(3).
10. Eiden S, Daniel C, Steinbrueck A, Schmidt I, Simon E. Salmon calcitonin - a potent inhibitor of food intake in states of impaired leptin signalling in laboratory rodents. *J Physiol*. 2002; 541(Pt 3): 1041-8.

11. Engin A. The Mechanism of Leptin Resistance in Obesity and Therapeutic Perspective. *Obesity and Lipotoxicity*. 2024; 463-87.
12. Gelsomino L, Giordano C, Camera G, Sisci D, Marsico S, Campana A et al. Leptin Signaling Contributes to Aromatase Inhibitor Resistant Breast Cancer Cell Growth and Activation of Macrophages. *Biomolecules*. 2020; 10(4).
13. Gerrits AJ, Gitz E, Koekman CA, Visseren FL, van Haeften TW, Akkerman JW. Induction of insulin resistance by the adipokines resistin, Leptin, plasminogen activator inhibitor-1 and retinol-binding protein 4 in human megakaryocytes. *Haematologica*. 2012; 97(8): 1149-57.
14. Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L et al. Advancing precision medicine: A review of innovative In Silico approaches for drug development, clinical pharmacology and personalized healthcare. *Pharmaceutics*. 2024; 16 (3): 332.
15. Barros MT, Paci M, Tervonen A, Passini E, Koivumäki JT, Hyttinen J et al. From multiscale biophysics to digital twins of tissues and organs: future opportunities for in-silico pharmacology. *IEEE Transact Mol Biol Multiscale Comm*. 2024.
16. Olmedo DA, Durant-Archibold AA, López-Pérez JL, Medina-Franco JL. Design and Diversity analysis of chemical libraries in drug discovery. *Combin Chem High Screen*. 2024; 27(4): 502-15.
17. Hosaka S, Yamada T, Takahashi K, Dan T, Kaneko K, Kodama S et al. Inhibition of Plasminogen Activator Inhibitor-1 Activation Suppresses High Fat Diet-Induced Weight Gain via Alleviation of Hypothalamic Leptin Resistance. *Front Pharmacol*. 2020; 11: 943.
18. Huang Z, Liu C, Zheng G, Zhang L, Zhong Q, Zhang Y et al. Articular Cartilage Regeneration via Induced Chondrocyte Autophagy by Sustained Release of Leptin Inhibitor from Thermo-Sensitive Hydrogel through STAT3/REDD1/mTORC1 Cascade. *Adv Healthc Mater*. 2023; 12(30): e2302181.
19. Huang Z, Liu C, Zheng G, Zhang L, Zhong Q, Zhang Y et al. Correction to "Articular Cartilage Regeneration via Induced Chondrocyte Autophagy by Sustained Release of Leptin Inhibitor from Thermo-Sensitive Hydrogel Through STAT3/REDD1/mTORC1 Cascade". *Adv Healthc Mater*. 2024; 13(7): e2304470.
20. Ito Y, Fukui M, Kanda M, Morishita K, Shoji Y, Kitao T et al. Therapeutic effects of the allosteric protein tyrosine phosphatase 1B inhibitor KY-226 on experimental diabetes and obesity via enhancements in insulin and Leptin signaling in mice. *J Pharmacol Sci*. 2018; 137(1): 38-46.
21. Shelake G, Baviskar S, Panda AK, Solankure S, Pandey K, Chauthe S et al. Exploring the rare variants associated with Type 2 Diabetes Mellitus in Indian population and its disease-drug association studies: an in-silico approach. *J Biomol Struct Dynamics*. 2024; 42(12): 6307-22.
22. Itrat N, Nazir A, Saif K, Mushtaq Z, Nisa MU, Habib A, et al. Antidiabetic Flavonoids from Natural Sources. *Adv Pharmacogn Phytochem Diabetes*. 2024; 44.
23. Almathen F, Charruau P, Mohandesan E, Mwacharo JM, Orozco-terWengel P, Pitt D et al. Ancient and modern DNA reveal dynamics of domestication and cross-continental dispersal of the dromedary. *Proc Natl Acad Sci U S A*. 2016; 113(24): 6707-12.
24. Alrashdi I. Fog-based deep learning framework for real-time pandemic screening in smart cities from multi-site tomographies. *BMC Med Imaging*. 2024; 24(1): 123.
25. Amenu K, Agga GE, Kumbe A, Shibiru A, Desta H, Tiki W et al. MILK Symposium review: Community-tailored training to improve the knowledge, attitudes, and practices of women regarding hygienic milk production and handling in Borana pastoral area of southern Ethiopia. *J Dairy Sci*. 2020; 103(11): 9748-57.
26. Wang W, Melnikov F, Napoli J, Desai P. Advances in the Application of In Silico ADMET Models—An Industry Perspective. *Computational Drug Discovery: Methods and Applications*. 2024; 2: 495-535.
27. Ahmed MH, Karkush SI, Ali SA, Mohammed AA. Phytochemicals: a new arsenal in drug discovery. *Int J Med Sci Dent Health*. 2024; 10(01): 29-44.
28. Mohammed ED, Zhang Z, Tian W, Gangarapu V, Al-Gendy AA, Chen J et al. Modulation of IR as a therapeutic target to prevent NASH using NRF from *Diceratella elliptica* (DC.) jonsell. Strong Nrf2 and leptin inducer as well as NF-kB inhibitor. *Phytomedicine*. 2021; 80: 153388.
29. Pieterse C, Schutte R, Schutte AE. Leptin links with plasminogen activator inhibitor-1 in human obesity: the SABPA study. *Hypertens Res*. 2015; 38(7): 507-12.
30. Pena-Leon V, Perez-Lois R, Maria V, Prida E, Moreno DM, Fernø J et al. Novel mechanisms involved in leptin sensitization in obesity. *Biochem Pharmacol*. 2024; 116:129.
31. Poullos E, Koukounari S, Psara E, Vasios GK, Sakarikou C, Giaginis C. Anti-obesity properties of phytochemicals: Highlighting their molecular mechanisms against obesity. *Current Medicinal Chemistry*. 2024; 31(1): 25-61.
32. Szekeres Z, Sandor B, Bogнар Z, Ramadan FHJ, Palfi A, Bodis B et al. Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes. *Int J Mol Sci*. 2023; 24(5).

33. Mandal AK, Sahoo A, Almalki WH, Almuji SS, Alhamyani A, Aodah A, et al. Phytoactives for Obesity Management: Integrating Nanomedicine for Its Effective Delivery. *Nutrition Reviews*. 2024; nuae136.
34. Md Mokhtar AH, Malik IA, Abd Aziz NAA, Almabhouh FA, Durairajanayagam D, Singh HJ. LY294002, a PI3K pathway inhibitor, prevents leptin-induced adverse effects on spermatozoa in Sprague-Dawley rats. *Andrologia*. 2019; 51(3): e13196.
35. Medeiros AF, Costa IS, Carvalho FMC, Kiyota S, Souza BBP, Sifuentes DN et al. Biochemical characterization of a Kunitz-type inhibitor from *Tamarindus indica* L. seeds and its efficacy in reducing plasma leptin in an experimental model of obesity. *J Enzyme Inhib Med Chem*. 2018; 33(1): 334-48.
36. Kawsar S, Munia NS, Saha S, Ozeki Y. In Silico Pharmacokinetics, Molecular Docking and Molecular Dynamics Simulation Studies of Nucleoside Analogs for Drug Discovery-A Mini Review. *Mini Rev Medicinal Chemistry*. 2024; 24(11): 1070-88.
37. Muhammed MT, Aki-Yalcin E. Molecular docking: principles, advances, and its applications in drug discovery. *Letters in Drug Design & Discovery*. 2024; 21(3): 480-95.

